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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the effects of natriuretic peptide (NP)-guided treatment in people with cardiovascular risk factors (without heart failure).
B A C K G R O U N D
Description of the condition
Cardiovascular disease (CVD) is the leading cause ofmortality and
morbidity globally, and remains the foremost cause of preventable
death (Santulli 2013; WHO 2016). An estimated 17.5 million
people died from CVD in 2012, representing 31% of all global
deaths (WHO 2016). In Europe, close to half of all deaths are
caused by CVD (Nichols 2014), and the estimated cost to the EU
economy is EUR 169 billion annually (HERC 2012).
The prevalence of CVD is set to increase further as a result of the
epidemic of obesity, diabetes, hypertension anddyslipidaemia (dis-
turbance in lipidmetabolism leading to changes in plasma lipopro-
tein function and/or levels) (Go 2104; Piepoli 2016; Santulli
2013). One-quarter of adults aged 50 years have at least one risk
factor for the development of CVD (Lloyd-Jones 2006). Accord-
ing to the AmericanHeart Association, nearly 35% of adults in the
USA have obesity (body mass index (BMI) ≥ 30 kg/m2), almost
40% have dyslipidaemia, 33% have hypertension, 8.3% have di-
abetes, and 38% have abnormal fasting glucose or pre-diabetes
(Go 2104). For people free of CVD at 50 years of age, more than
half of men and nearly 40% of women will develop CVD during
their remaining lifespan (Lloyd-Jones 2006). Diabetes confers the
highest lifetime risk for CVD of any single risk factor (Lloyd-Jones
2006), with hypertension, dyslipidaemia and obesity also identi-
fied as increased risk factors (Go 2104; Lloyd-Jones 2006; Piepoli
2016; Santulli 2013).
People with CVD who are at high cardiovascular risk need early
identification (WHO 2016). Present day approaches, focusing
mainly on risk factor intervention, have brought about some re-
duction in cardiovascular morbidity and mortality, but have fallen
short of targets (Ebrahim 2011; Krogsbøll 2012).
In the setting of a worldwide increase in life expectancy and the
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continuing rise in CVD risk factors, the uniform direction of
resources to a population of predominantly lower-risk patients,
poses a major threat to the sustainability of healthcare systems.
Evidence suggests that natriuretic peptide (NP) is effective in re-
fining risk prediction for CVD, adding predictive power to con-
ventional risk factors (McGrady 2013; Onodera 2012; Tarnow
2006; Wang 2004). Conventional risk indicators reflect potential
for cardiovascular insult, e.g. lipids or hypertension, whereas NP
is a response to established cardiovascular stress or damage.
Refining risk prediction with the aid of NP may have advantages
in identifying those at highest risk of CVD over conventional
risk indicators. Focusing intensive follow-up in individuals with
increased NP levels would be a more sustainable use of resources.
Description of the intervention
The intervention is the measurement of plasma NP levels (B-
Type natriuretic peptide (BNP and NT-proBNP)) in people with
risk factors for CVD or established CVD (but neither known
asymptomatic left ventricular systolic dysfunction nor overt heart
failure at baseline), in order to predict those most at risk of CVD.
NP levels that indicate an increased risk of CVD are BNP > 35
picograms per millilitre (pg/mL), or NT-proBNP > 125 pg/mL,
or both (as considered by the European Society of Cardiology to
be the upper limit of normal in the non-acute heart failure setting)
(Ponikowski 2016).
This screening is followed by NP-guided treatment for those ran-
domised to the intervention group and standard care for the con-
trol group.
NP-guided treatment includes modification and optimisation of
pharmacological therapy, diagnostic and investigation strategies,
and education and lifestyle interventions based onNP levels that is
supplementary to the care provided in the control group. Standard
care is defined as local guideline-based care, includingmodification
of pharmacological, education and lifestyle interventions, while
not taking into account the NP level.
How the intervention might work
Modulation of traditional risk factors (e.g. hypertension, hyper-
cholesterolaemia) have improved cardiovascular outcomes in at-
risk individuals, but there is still residual risk (Ebrahim 2011;
Krogsbøll 2012).
BNP/NT-proBNP is amember of the family of genetically distinct
NPs synthesised and released by cardiomyocytes in response to var-
ious stimuli, including myocyte stretch due to volume expansion
and pressure overload, ischaemia (reduced coronary blood sup-
ply to the heart), fibrosis and inflammation (Maeda 1998; Phelan
2012; Sabatine 2004; Yoshimura 1993). Increases in plasma BNP/
NT-proBNP concentration have diagnostic and prognostic impli-
cations in selected populations, as demonstrated initially in heart
failure, and subsequently in early stage and asymptomatic disease
(Eurlings 2010; Gardner 2003; Kearley 2011).
NP is superior to traditional CVD risk factors, such as hyperc-
holesterolaemia and hypertension in identifying those at risk of
heart failure (Clerico 2007), acute coronary syndrome (Glaser
2011; Scirica 2011), and coronary heart disease (Mishra 2014).
New data suggest that NP screening and early intervention may
prevent heart failure (Yancy 2017).
Measurement of NP level to identify those at greatest risk of car-
diovascular events followed by targeted intensive risk reduction
(including pharmacotherapy, diagnostic and investigation strate-
gies and lifestyle and education interventions) may reduce the oc-
currence of major adverse cardiovascular events (MACE) in this
population. (While themost commonly used endpoint for cardio-
vascular research, there is no standard definition for MACE and
individual outcomes used to make this composite endpoint vary
by study (Kip 2008).
Why it is important to do this review
NP-guided treatment for the optimisation of heart failure man-
agement is well established (Ponikowski 2016; Yancy 2013), and
is the subject of a Cochrane Review (Kearley 2011).
Evidence for the use of NPs to identify and deliver a targeted in-
tervention to an at-risk population is emerging, but this approach
to CVD and heart failure prevention is not yet part of routine
clinical care.
The 2014 Canadian Cardiovascular Society Heart Failure Man-
agement Guidelines suggest that “in individuals with risk factors
for the development of heart failure, NP levels be used to imple-
ment strategies to prevent heart failure” (Moe 2015). The 2017
American Guidelines for the Management of Heart Failure, issue
a ’moderate’ recommendation that “for patients at risk of devel-
oping heart failure, NP-based screening followed by team-based
care can be useful to prevent the development of left ventricu-
lar dysfunction (systolic or diastolic) or new-onset heart failure”
(Yancy 2017). Due to the limited scientific evidence and clinical
experience in this area, it is difficult for guidelines to provide a
clear consensus or specific recommendations on NP screening to
physicians. In this review, we would like to collate, and through
meta-analysis, strengthen the existing body of evidence for this
approach to CVD prevention and allow clearer recommendations
to be made.
O B J E C T I V E S
To assess the effects of natriuretic peptide (NP)-guided treatment
in people with cardiovascular risk factors (without heart failure).
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M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include all randomised controlled trials (RCTs).
Types of participants
We will include adults (≥18 years of age) with risk factors for the
development of cardiovascular disease (CVD). We will consider
the following risk factors.
• Hypertension.
• Hypercholesterolaemia.





• Valvular heart disease.
• Elevated levels of NP, defined as BNP > 35 pg/mL, or
NTproBNP > 125 pg/mL, or both (as considered by the
European Society of Cardiology to be the upper limit of normal
in the non-acute heart failure setting (Ponikowski 2016). We will
include NP measured using any assay.
Wewill not consider lifestyle risk factors, such as sedentary lifestyle,
diet, smoking and alcohol intake. We will include all healthcare
settings (e.g. hospital, community).
We will exclude people with symptomatic heart failure at baseline,
diagnosed by an established reference standard, such as echocar-
diography, cardiac magnetic resonance imaging, or specialist opin-
ion using reference criteria, e.g. Framingham (McKee 1971), or a
combination of these. At baseline we will exclude people being in-
vestigated for a possible diagnosis of symptomatic heart failure or
people with any evidence of asymptomatic left ventricular systolic
dysfunction (left ventricular ejection fraction < 50%) at baseline.
We will contact trialists (study authors) to request a full dataset if
only a subset of eligible participants are presented. If trialists are
unwilling or unable to provide additional information, we will not
include the study in meta-analysis.
Types of interventions
We will include RCTs comparing NP-based screening (to identify
patients at increased risk of developing a cardiac event) and subse-
quent NP-guided treatment with standard care. NP-guided treat-
ment includes modification and optimisation of pharmacological
therapy (as defined by the trialists), diagnostic and investigation
strategies, and education and lifestyle interventions based on NP
levels that is supplementary to the care provided in the control
group. We will include studies that involve any element of NP-
guided treatment. Standard care is defined as local guideline-based
care, including modification of pharmacological, education and
lifestyle interventions, while not taking into account the partici-
pant’s NP level.
Types of outcome measures
Reporting one or more of the outcomes listed here in the trial is
not an inclusion criterion for the review. We will assess outcomes
at the end of follow-up.
Primary outcomes
1. Cardiovascular mortality (as defined by trialists)
2. Cardiovascular hospitalisation (as defined by trialists)
Secondary outcomes
1. Cardiovascular mortality
2. Cardiovascular hospitalisation (all occurrences)
3. Ventricular dysfunction (as defined by trialists)
4. All-cause hospitalisations (all occurrences)
5. All-cause mortality
6. Change in NP level at the end of follow-up
Search methods for identification of studies
Electronic searches
Wewill identify trials through systematic searches of the following
bibliographic databases.
• Cochrane Central Register of Controlled Trials
(CENTRAL) in the Cochrane Library
• MEDLINE (Ovid)
• Embase (Ovid)
• Web of Science Conference Proceedings Citation Index -
Science (Thomson Reuters)
We will adapt the preliminary search strategy for MEDLINE
(Ovid) for use in the other databases (Appendix 1). We will ap-
ply the Cochrane sensitivity-maximising RCT filter to MED-
LINE (Ovid) and adaptations of it to Embase andWeb of Science
(Lefebvre 2011).
We will also conduct a search of ClinicalTrials.gov (
www.ClinicalTrials.gov), the EU Clinical Trials Register (
www.clinicaltrialsregister.eu), and theWorldHealthOrganization
(WHO) International Clinical Trials Registry Platform (ICTRP)
Search Portal (apps.who.int/trialsearch), for ongoing or unpub-
lished trials.
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We will search all databases from their inception to the present,
and we will impose no restriction on language of publication.
Searching other resources
We will check reference lists of all primary studies and review
articles for additional references.We will also examine any relevant
retraction statements and errata for included studies.
Data collection and analysis
Selection of studies
Two review authors (FR, CK) will independently screen titles and
abstracts for inclusion of all the potential studies we identify as a
result of the search and code them as ’retrieve’ (eligible or poten-
tially eligible/unclear) or ’do not retrieve’. If there are any disagree-
ments, a third review author will be asked to arbitrate (CR). We
will retrieve the full-text study reports/publication and two review
authors (FR, CK) will independently screen the full-text and iden-
tify studies for inclusion, and identify and record reasons for ex-
clusion of the ineligible studies. We will resolve any disagreement
through discussion or, if required, we will consult a third review
author (CK). We will identify and exclude duplicates and collate
multiple reports of the same study so that each study rather than
each report is the unit of interest in the review. We will record the
selection process in sufficient detail to complete a PRISMA flow
diagram and ’Characteristics of excluded studies’ table (Liberati
2009).
Data extraction and management
We will use a data collection form for study characteristics and
outcome data which has been piloted on at least one study in the
review. One review author (FR) will extract the following study
characteristics from included studies.
1. Methods: study design, total duration of study, details of
any ’run in’ period, number of study centres and location, study
setting, and date of study.
2. Participants: number of participants randomised, number
of participants completing the study period, and number of
participant withdrawals, mean age, age range, gender, severity of
condition (as defined by the trialists), diagnostic criteria,
inclusion criteria, and exclusion criteria.
3. Interventions: intervention, comparison, concomitant
medications, and excluded medications.
4. Outcomes: primary and secondary outcomes specified and
collected, and time points reported.
5. Notes: funding for trial, and notable conflicts of interest of
trial authors.
Two review authors (FR, CK) will independently extract outcome
data from included studies. Disagreements will be resolved by
consensus or by involving a third review author (CR). One review
author (FR)will transfer data into the ReviewManager 5 (RevMan
5) file (ReviewManager 2014).We will double-check that data are
entered correctly by comparing the data presented in the review
with the study reports. A second review author (CK) will spot-
check study characteristics for accuracy against the trial report.
Assessment of risk of bias in included studies
Two review authors (FR, CK) will independently assess risk of bias
for each study using the criteria outlined in the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2017), and
provide a summary judgement for each study. We will resolve any
disagreements by discussion or by involving another review author
(CR). We will assess the risk of bias according to the following
domains.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias.
We will judge each potential source of bias as high, low or un-
clear and provide a quote from the study report together with a
justification for our judgement in the ’Risk of bias’ table. We will
summarise the ’Risk of bias’ judgements across different studies
for each of the domains listed. Where information on risk of bias
relates to unpublished data or correspondence with a trialist, we
will note this in the ’Risk of bias’ table.
When considering treatment effects, we will take into account the
risk of bias for the studies that contribute to that outcome. For
our sensitivity analysis, we will exclude studies that are at high or
unclear risk of bias for random sequence generation, allocation
concealment, and incomplete data.
Assessment of bias in conducting the review
We will conduct the review according to this published protocol
and report any deviations from it in the ’Differences between pro-
tocol and review’ section of the review.
Measures of treatment effect
For dichotomous outcome data, we will calculate the effect size as
risk ratios (RRs) with 95% confidence intervals (CIs).
For continuous variables, we will use standardised mean differ-
ences (SMD with 95% CIs) if study authors use different mea-
surement scales. If continuous outcomes are measured using the
same measurement scales, we will convert data will into mean dif-
ferences (MDs) and present with 95% CIs. We will enter data
4Natriuretic peptide-guided treatment for the prevention of cardiovascular events in patients without heart failure (Protocol)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
appearing as a scale with a consistent direction of effect. Where
skewed continuous outcomes are present, we will present medians
and interquartile ranges.
In the event of missing summary data, e.g. missing standard de-
viations (SDs), we will obtain these, where possible, using calcu-
lations provided in the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2017).
Unit of analysis issues
We do not anticipate unit of analysis issues. If we identify any
non-standard designs (e.g. crossover or cluster randomised trials)
we will use recommendations from the Cochrane Handbook for
Systematic Review of Interventions (Higgins 2017).
Dealing with missing data
Where data are missing, wewill contact authors/investigators in an
attempt to obtain these data and verify critical study characteristics
(e.g. when a study can only be identified via the abstract). Where
this is not possible, and the missing data are thought to introduce
serious bias, we will explore the impact of including such studies
in the overall assessment of results by a sensitivity analysis. We will
extract data on both change frombaseline and final value outcomes
(depending on what the study has reported) if the required means
and SDs are available. If a SD is not available, then we will use
the standard error or CIs for group means to calculate the SD. If
a SD is not available or it is not possible to calculate it, then we
will exclude this from any meta-analysis.
Assessment of heterogeneity
We will assess statistical heterogeneity visually and by using the
I² statistic. We will conduct a fixed-effect meta-analysis if no het-
erogeneity is present, otherwise, if we identify substantial hetero-
geneity (I² > 50%) we will employ a random-effects model, pro-
vide possible interpretations by reporting the clinical heterogene-
ity, e.g. descriptive summary of the participants, study designs and
interventions carried out in each analysis, and will explore possible
causes by conducting prespecified subgroup analyses (Ryan 2016;
detailed in Subgroup analysis and investigation of heterogeneity).
Assessment of reporting biases
If we are able to pool more than 10 trials, we will create and
examine a funnel plot to explore possible small study biases for
the primary outcomes (Sedgwick 2013).
Data synthesis
We will employ a fixed-effect meta-analysis when no substantial
heterogeneity is present (I² < 50%), otherwise we will use a ran-
dom-effects model (see Assessment of heterogeneity above). We
will provide a narrative description of parameters describing clin-
ical heterogeneity (e.g. study designs) as above.
’Summary of findings’ table
We will create a ’Summary of findings’ table using the follow-
ing primary and secondary outcomes: cardiovascular mortality (as
defined by trialists), cardiovascular hospitalisation (as defined by
trialists), ventricular dysfunction (as defined by trialists), all-cause
hospitalisations, all-cause mortality, and change in NP level from
baseline. We will create a ’Summary of findings’ table with these
outcomes (see Table 1).
We will use the five GRADE considerations (study limitations,
consistency of effect, imprecision, indirectness and publication
bias) to assess the certainty of a body of evidence as it relates to
the studies which contribute data to the meta-analyses for the pre-
specified outcomes. We will use methods and recommendations
described in Section 8.5 and Chapter 12 of the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2017), using
GRADEpro GDT software (GRADEpro GDT 2015). We will
justify all decisions to downgrade or upgrade the certainty of stud-
ies using footnotes and we will make comments to aid reader’s
understanding of the review where necessary. Two review authors
(FR, CK) will undertake this assessment independently. Disagree-
ments will be resolved by consensus or my involving a third review
author (CR).
Subgroup analysis and investigation of heterogeneity
If there are sufficient data, we will perform subgroup analyses for
the primary outcome for the following.
1. Age (≥ 65 years and < 65 years).
2. Gender (NP is higher in females).
3. Diabetes mellitus (NP is higher in diabetes mellitus).
4. Obesity (BMI ≥ 30 kg/m2 versus BMI < 30 kg/m2).
5. Atrial fibrillation versus non-atrial fibrillation.
6. Valvular heart disease versus non-valvular heart failure.
7. Ischaemic heart failure versus non-ischaemic heart failure.
8. NP levels at baseline to classify subgroups (BNP 35 pg/mL
to 100 pg/mL and ≥ 100 pg/mL; NT-proBNP 125 pg/mL to
300 pg/mL and ≥ 300 pg/mL). The lower limit for these
subgroups is derived from the European Society of Cardiology
Guidelines (Ponikowski 2016), and the upper limit for these
subgroups represent the cut-off points for the implementation of
strategies to prevent heart failure, as specified in the 2014
Canadian Cardiovascular Society Heart Failure Management
Guidelines (Moe 2015).
9. Renal function (estimated Glomerular Filtration Rate
(eGFR) ≥ 60 ml/min/1.73m2 or < 60 ml/min/1.73m2 as
measured by the Cockcroft and Gault or Modification of Diet in
Renal Disease (MDRD) formula)
Older age, female gender and diabetes are associated with higher
NP levels (Raymond 2003; Wang 2002).
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We will use the primary outcome in subgroup analyses, i.e. car-
diovascular mortality and cardiovascular hospitalisation.
We will use the formal statistical test for heterogeneity across sub-
groups based on the random-effects model to test for subgroup
interactions (Borenstein 2008) and we will use caution in the in-
terpretation of subgroup analyses, as advised in Section 9.6 of
the Cochrane Handbook for Systematic Reviews of Interventions
(Deeks 2017).
Sensitivity analysis
We will conduct sensitivity analyses to test the robustness of the
results using the results of the ’Risk of bias’ assessment. We will ex-
clude studies that are at high or unclear risk of bias for random se-
quence generation, allocation concealment, and incomplete data.
Reaching conclusions
We will base our conclusions only on findings from the quantita-
tive or narrative synthesis of included studies for this review. We
will avoid making recommendations for practice and our impli-
cations for research will suggest priorities for future research and
outline any remaining uncertainties in the area.
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A D D I T I O N A L T A B L E S
Table 1. ’Summary of findings’ table - draft
Natriuretic peptide-based screening and subsequent NP-guided treatment compared to standard care for prevention of cardiovascular
mortality and hospitalisation in those with cardiovascular risk factors
Patient or population: people with cardiovascular risk factors
Setting: any
Intervention: natriuretic peptide-based screening and subsequent NP-guided treatment
Comparison: standard care
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NP level at the
end of follow-up
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and
the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio; OR: odds ratio;
GRADE Working Group grades of evidence
High-certainty: we are very confident that the true effect lies close to that of the estimate of the effect
Moderate-certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the
effect, but there is a possibility that it is substantially different
Low-certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the
effect
Very low-certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the
estimate of effect
9Natriuretic peptide-guided treatment for the prevention of cardiovascular events in patients without heart failure (Protocol)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A P P E N D I C E S
Appendix 1. Preliminary MEDLINE (Ovid) search strategy
1 Natriuretic Peptide, Brain/








10 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9
11 randomized controlled trial.pt.
12 controlled clinical trial.pt.
13 randomized.ab.
14 placebo.ab.
15 clinical trials as topic.sh.
16 randomly.ab.
17 trial.ti.
18 11 or 12 or 13 or 14 or 15 or 16 or 17
19 exp animals/ not humans.sh.
20 18 not 19
21 10 and 20
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